Loading clinical trials...

A Pharmacodynamic Study With Ticagrelor in African American Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE4

A Pharmacodynamic Study With Ticagrelor in African American Patients

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease

NCT01523392•AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.

Detailed Description

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Provision of signed and dated informed consent before initiation of any study-related procedures
•Male or female patients aged 18 years or older
•Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
•Females must be post menopausal or surgically sterile Self-identified as African American

Exclusion Criteria

•Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
•Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
•Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis

Locations (8)

Research Site

Newark, Delaware, United States

Research Site

Wilmington, Delaware, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Hollywood, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Towson, Maryland, United States

Research Site

Beaumont, Texas, United States

Key Dates

Start Date

March 1, 2012

Primary Completion Date

September 1, 2013

Completion Date

September 1, 2013

Last Updated

October 8, 2014

Enrollment

ACTUAL participants

Conditions

Stable Coronary Artery Disease

Interventions

Ticagrelor

DRUG

Clopidogrel

DRUG

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

NCT07195149

Chronic Coronary SyndromeStable Coronary Artery Disease CAD

View study

NOT_YET_RECRUITINGPHASE1

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease

NCT07431294

Stable Coronary Artery Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pharmacodynamic Study With Ticagrelor in African American Patients

Inclusion Criteria

Exclusion Criteria

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease

Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models

Angina Prevalence and Provider Evaluation of Angina Relief

Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve Quality